(Q46728120)

24 December 2017

title

In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine (English)

1 reference

24 December 2017

author name string

Evelyn D Lobo

1

1 reference

24 December 2017

Richard F Bergstrom

2

1 reference

24 December 2017

Shobha Reddy

3

1 reference

24 December 2017

Tonya Quinlan

4

1 reference

24 December 2017

Jill Chappell

5

1 reference

24 December 2017

Quan Hong

6

1 reference

24 December 2017

Barbara Ring

7

1 reference

24 December 2017

Mary Pat Knadler

8

1 reference

24 December 2017

publication date

1 January 2008

1 reference

24 December 2017

Clinical Pharmacokinetics

published in

1 reference

24 December 2017

volume

47

1 reference

24 December 2017

issue

3

1 reference

24 December 2017

page(s)

191-202

1 reference

24 December 2017

https://scigraph.springernature.com/pub.10.2165/00003088-200847030-00005

exact match

0 references

cites work

LY248686, a new inhibitor of serotonin and norepinephrine uptake.

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003088-200847030-00005

Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003088-200847030-00005

The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate

21 January 2018

1 reference

12 December 2020

A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.

1 reference

12 December 2020

Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2.

1 reference

12 December 2020

A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers.

1 reference

12 December 2020

Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers

1 reference

12 December 2020

Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities

1 reference

12 December 2020

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

1 reference

12 December 2020

A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain

1 reference

12 December 2020

An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group.

1 reference

12 December 2020

Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (I-QOL)

1 reference

12 December 2020

Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction

1 reference

12 December 2020

Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects

1 reference

12 December 2020

Development and validation of a liquid chromatography-tandem mass spectrometric method for the determination of the major metabolites of duloxetine in human plasma

1 reference

12 December 2020

Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex

1 reference

12 December 2020

Blockade of the serotonin and norepinephrine uptake processes by duloxetine: in vitro and in vivo studies in the rat brain.

1 reference

12 December 2020

Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo

1 reference

12 December 2020

Duloxetine vs. placebo in patients with painful diabetic neuropathy

1 reference

12 December 2020

Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions

1 reference

12 December 2020

Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine.

1 reference

12 December 2020

Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor.

1 reference

12 December 2020

Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.

1 reference

12 December 2020

Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain

1 reference

12 December 2020

Treatment of overactive bladder: other drug mechanisms

1 reference

12 December 2020

Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

1 reference

12 December 2020

Effect of age on the pharmacokinetics of duloxetine in women

1 reference

12 December 2020

Duloxetine Eli Lilly & Co.

1 reference

12 December 2020

Designing a new generation of antidepressant drugs

1 reference

12 December 2020

Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial

1 reference

12 December 2020

Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects

1 reference

12 December 2020

A retrospective pooled analysis of duloxetine safety in 23,983 subjects.

1 reference

12 December 2020

Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects

1 reference

12 December 2020

10.2165/00003088-200847030-00005

Identifiers

DOI

1 reference

24 December 2017

Dimensions Publication ID

0 references

1 reference

24 December 2017